UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): June 3, 2013

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware (State or Other Jurisdiction of Incorporation) **000-30319** (Commission File Number) 94-3265960 (I.R.S. Employer Identification Number)

901 Gateway Boulevard South San Francisco, California 94080 (650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act of 1934"), or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On June 5, 2013, Theravance, Inc. is scheduled to present at Jefferies 2013 Healthcare Conference in New York. A copy of the investor slide presentation is attached hereto as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit	Description
Exhibit 99.1	Theravance, Inc.'s Investor Slide Presentation at Jefferies 2013 Healthcare Conference

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THERAVANCE, INC.				
Date: June 3, 20	13 By: /s/ Michael W. Aguiar Michael W. Aguiar Chief Financial Officer			
	3			
EXHIBIT INDEX				
<u>Exhibit No.</u> 99.1	Description Theravance, Inc.'s Investor Slide Presentation at Jefferies 2013 Healthcare Conference			
	4			



Medicines That Make a Difference®

NASDAQ: THRX

Jefferies 2013 Healthcare Conference

June 5, 2013

THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.

© 2013 Theravance, Inc. All rights reserved.



This presentation contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Theravance intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to: plans for executing the separation of Theravance into two independent companies, the expected timing of the separation, expectations for the amount and estimated duration of the funding of Theravance Biopharma at the time of the separation, the strategies, plans and objectives of the two companies following the separation, expectations related to the staffing of the two companies, the expected timing of the Elan shareholder vote on the proposed royalty participation transaction and the outcome of such vote, the expected timing for consummating the royalty participation transaction if Elan shareholder approval is obtained, the effect of the royalty participation transaction if it is consummated on the strategies, plans and objectives of Theravance, the timing, manner and amount of anticipated potential returns of capital to stockholders if the royalty participation transaction and/or the separation is consummated, the possible tax effects of the royalty participation transaction and/or the separation, the status and timing of clinical studies, data analysis and communication of results, the potential benefits and mechanisms of action of product candidates, the enabling capabilities of Theravance's approach to drug discovery and its proprietary insights, expectations for product candidates through development and commercialization, and the timing of seeking regulatory approval of product candidates. These statements are based on the current estimates and assumptions of the management of Theravance as of the date of this presentation and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: delays in preparing audited financial statements for Theravance Biopharma, difficulties in effecting the registration of Theravance Biopharma as a public company, failure to obtain necessary consents from third parties, changes in the development or operations of Theravance prior to the separation that could affect the plans for the separation or the cash available for the initial funding of the independent companies, delays encountered in obtaining, or the failure to obtain, a private letter ruling from the Internal Revenue Service (should Theravance seek to effect the separation on a tax-free basis) or approval of Elan's shareholders for the royalty participation transaction, the possibility that intervening events could arise which could alter the timing, or the ability to consummate, the royalty participation transaction, the anticipated separation of Theravance into two independent companies or the intended return of capital to stockholders, the risk that third parties could challenge the royalty participation transaction, the risk that Theravance's net operating loss may not be available to offset taxes from the royalty participation transaction, the potential that results from clinical or non-clinical studies indicate product candidates are unsafe or ineffective, our dependence on third parties to conduct our clinical studies, delays or failure to achieve regulatory approvals for product candidates, and risks of collaborating with third parties to discover, develop and commercialize products. Other risks affecting Theravance are described under the heading "Risk Factors" contained in Theravance's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 1, 2013 and the risks discussed in our other periodic filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance assumes no obligation to update its forward-looking statements. Theravance



Theravance Today





► ANORO[™] ELLIPTA[™] FDA PDUFA goal date December 18, 2013, regulatory applications in COPD filed globally

rently approved anywhere in the world. RELVAR™, BREO™, ANORO™ and ELLIPTA™ are trademarks of the G

Theravance

GSK pays upward tiering 6.5% to 10% royalties on WW net sales



ELLIPTA™ (FF/VI) and ANORO™ ELLIPTA™ (UMEC/VI) are in


Deep Pipeline

- Strong Financial Position: \$558 million at March 31, 2013
- Royalty Participation Agreement with Elan
 Acceleration of return of capital to stockholders

BREO™ ELLIPTA™ FDA Approved for COPD; BREO™ ELLIPTA™ is not indicated for the relief of acute bronchospasm or the treatment of asthma.


Royalty Participation Agreement with Elan


- Elan to purchase a participation interest in potential future royalty payments related to four respiratory programs partnered with GSK
 - RELVAR™ ELLIPTA™/BREO™ ELLIPTA™
 - ANORO™ ELLIPTA™
 - MABA Monotherapy, GSK961081 ('081)
 - VI Monotherapy
 - Excludes MABA/ICS and UMEC/VI/FF
- Significant public data available for all four programs
- Programs to address significant portion of global COPD/asthma markets of approximately \$20B* in 2012
- Long-Term Growth Potential: Royalty term, later of 15 years from launch or expiration of patent exclusivity on a country-by-country and product-by-product basis
- If approved by Elan shareholders, Elan will make a one-time \$1.0B cash payment to Theravance for a 21% participation interest in potential future royalty payments earned by Theravance from the four programs when, as and if received




Significant Respiratory Market Opportunity


Global Sales* of Products Containing Long-Acting Bronchodilators (USD, in billions) 12-Month Periods Ending














Management of COPD – Pharmacological 1st choice

GOLD 4 GOLD 3	C ICS/LABA or THE BEST BRONCHODILATOR	D ICS/and THE BEST BRONCHODILATOR	2 or more exac/ year
GOLD 2	A SABA or SAMA prn	B THE BEST BRONCHODILATOR	Less than 2 exac/ year
GOLD 1			
	mMRC 0-1 CAT <10	mMRC ≥ 2 CAT ≥ 10	-





One Common Dry Powder Inhaler



GSK Respiratory Partnership



LABA Collaboration

► RELVAR[™] ELLIPTA[™]/ BREO[™] ELLIPTA[™] and VI

- GSK pays 15% royalty on first \$3.0B of annual WW net sales; 5% thereafter
- ► ANORO™ ELLIPTA™ (Launched after RELVAR™ ELLIPTA™/ BREO™ ELLIPTA™)
 - GSK pays upward tiering 6.5% to 10% royalties on WW net sales
- Potential milestone payments to GSK: up to \$220M
 - Divided by approval, launch, region and product

Strategic Alliance

MABA (GSK961081)

- Potential milestone payments to Theravance
 - \$10M for successful completion of Phase 2 combination program
 - \$25M per program for initiation of single and combination Phase 3 programs
- GSK pays royalty of 10% to 20% of WW net sales up to \$3.5bn and 7.5% thereafter





Separating into Two Highly Focused Businesses Provides Opportunity to Increase Stockholder Value

Royalty Management Co Theravance Biopharma **Business Objectives Business Objectives** Manage all development and commercial responsibilities Focus on the discovery, development and under the LABA collaboration with GSK and associated commercialization of small-molecule medicines in areas potential near-term respiratory product royalty revenues of significant unmet medical need with the intention of returning capital to stockholders Continue partnered programs, including cardiovascular BREO™ ELLIPTA™ approved for COPD in the US in collaboration with Merck and partnerships with Alfa May 2013/RELVAR™ ELLIPTA™ under review in EU -Wassermann, Clinigen and R-Pharm Potential short path to profitability Led by experienced leadership team Lean operations, minimal staffing Maintain current integrated R&D capabilities Programs Programs RELVAR™ELLIPTA™/ MABA /ICS* **BREO™ELLIPTA™** UMEC/VI/FF ANORO[™] ELLIPTA[™] ¥ TD-1211: OIC VI monotherapy TD-9855: ADHD and Fibromyalgi Two Companies with Distinct Business Objectives and Profiles

*This program will be held & managed by a limited liability company subsidiary of Royalty Management Co (the "LLC") and all of the LLC's economic interests in this program will accrue to Royalty Management Co. * These programs, partnered with GSK, will be held & managed by the LLC and 98% of the LLC's economic interests in these programs will accrue to Theravance Biopharma and 2% will accrue to Royalty Management Co.

BIODINATING and DS with accurate to Royally management Co. BREOTH ELLIPTATM FDA Approved for COPD; BREOTH ELLIPTATM is not indicated for the relief of acute bronchospasm or the treatment of asthma. RELIVARTM ELLIPTATM (FV) and ANCROTM ELLIPTATM (MECVI) are investigational medicines and are not currently approved anywhere in the world. RELIVARTM BREOTM ANCROTM and ELLIPTATM are trademarks of the GlavoSmthKline group of

2013: Key Programs Pipeline

THERAPEUTIC AREA				
PROGRAM	PHASE 1	PHASE 2	PHASE 3	FILED
RESPIRATORY				
RELVAR™ ELLIPTA™ (FF/VI): CC	PD and Asthma			and the second second
ANORO™ ELLIPTA™ (UMEC/VI):	COPD			
GSK961081 (MABA): COPD		in the second second		
TD-4208 (LAMA): COPD				
BACTERIAL INFECTIONS				
TD-1792: Serious Gram+ Infections				
TD-1607: Serious Gram+ Infections				
CNS/PAIN				
TD-1211: Opioid-Induced Constipation	on			
TD-9855: ADHD and Fibromyalgia		and the second		
GI MOTILITY DYSFUNCTIO	N			
TD-5108 (velusetrag): GI Motility D	ysfunction			
TD-8954: GI Motility Dysfunction				
Demonstrated Proof-of-Concept	Pre-Proof-of-Concept	t		Therava



Significant Near-Term Catalysts in 2013 / 2014 For Each Business

Royalty Management Co	▶ BREO™ ELLIPTA™ GSK intends to launch in the US in Q3 '13
	 ANORO[™] ELLIPTA[™] FDA PDUFA goal date on December 18, 2013
	► RELVAR [™] ELLIPTA [™] potential EMA action on COPD and asthma: 2013
Theravance Biopharma	 MABA '081 monotherapy expected to advance into Phase 3 in 2013 MABA /ICS ('081/FF) and UMEC/VI/FF combinations advancing TD-9855 Phase 2 ADHD results anticipated late-2013 / 2014
BREO™ ELLIPTA™ FDA Approved for COP RELVAR™ ELLIPTA™ (FF/VI) and ANORO™ ELLIPTA™ companies. The use of the brand names ANORO™ and RE	D; BREO™ ELLIPTA™ is not indicated for the relief of acute bronchospasm or the treatment of asthma. Theravance® UMEC/VI) are investigational medicines and are not currently approved anywhere in the world. RELVAR™, BREO™, ANGRO™ and ELLIPTA™ are trademarks of the GlaxoSmithKine group of 14



Theravance[®]



Medicines That Make a Difference®

NASDAQ: THRX

THANK YOU



BREO[™] ELLIPTA[™] Important Safety Information

BREO ELLIPTA is contraindicated in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to either fluticasone furoate, vilanterol, or any of the excipients.

BREO ELLIPTA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD, or as rescue therapy for the treatment of acute episodes of bronchospasm, which should be treated with an inhaled, short-acting beta2-agonist.

BREO ELLIPTA should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medications containing LABAs, as an overdose may result.

Oropharyngeal candidiasis has occurred in patients treated with BREO ELLIPTA

An increase in the incidence of pneumonia has been observed in subjects with COPD receiving the fluticasone furoate/vilanterol combination, including BREO ELLIPTA 100 mcg/25 mcg, in clinical trials. There was also an increased incidence of pneumonias resulting in hospitalization. In some incidences these pneumonia events were fatal.

Patients who use corticosteroids are at risk for potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. A more serious or even fatal course of chickenpox or measles may occur in susceptible patients.

Particular care is needed for patients who have been transferred from systemically active corticosteroids to inhaled corticosteroids because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.

Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage of inhaled corticosteroids in susceptible individuals.

Caution should be exercised when considering the coadministration of BREO ELLIPTA with long-term ketoconazole and other known strong CYP3A4 inhibitors because increased systemic corticosteroid and cardiovascular adverse effects may occur.

Inhaled medicines can produce paradoxical bronchospasm, which may be life-threatening. Vilanterol, the LABA in BREO ELLIPTA, can produce clinically significant cardiovascular effects in some patients. Decreases in bone mineral density have been observed with long-term administration of products containing inhaled corticosteroids, as have glaucoma, increased intraocular pressure, and cataracts.

The most common adverse reactions (≥3% and more common than in placebo) reported in two 6-month clinical trials with BREO ELLIPTA (and placebo) were nasopharyngitis, 9% (8%); upper respiratory tract infection, 7% (3%); headache, 7% (5%); and oral candidiasis, 5% (2%). In addition to the events reported in the 6-month studies, adverse reactions occurring in ≥3% of the subjects treated with BREO ELLIPTA in two 1-year studies included COPD, back pain, pneumonia, bronchitis, sinusitis, cough, oropharyngita, arthralgia, hypertension, influenza, pharyngitis, diarrhea, peripheral edema, and pyrexia.

BREO ELLIPTA is not indicated for the relief of acute bronchospasm or the treatment of asthma. The safety and efficacy of BREO ELLIPTA in patients with asthma have not been established. Long-acting beta2-adrenergic agonists (LABAs), such as vilanterol, one of the active ingredients in BREO ELLIPTA, increase the risk of asthma-related death. A placebocontrolled trial with another LABA (salmeterol) showed an increase in asthma-related deaths in subjects receiving salmeterol. This finding with salmeterol is considered a class effect of all LABAs, including vilanterol.

Full US Prescribing Information, including BOXED WARNING and Medication Guide is available at us.gsk.com.



O^{re} and ELUPTA^{re} are trademarks of the GlaupSmithKine proup of companies. Full US Prescribing Information, including BOXED WARNING and Medication Guide for BREO^{re} ELUPTA^{re} is available at us, ork com-